Literature DB >> 10381856

Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy.

F Gadler1, C Linde, C Daubert, W McKenna, E Meisel, E Aliot, L Chojnowska, L Guize, D Gras, X Jeanrenaud, L Kappenberger.   

Abstract

AIMS: Atrioventricular synchronous pacing exerts beneficial effects, including reduction of left ventricular outflow tract gradients, in patients with hypertrophic obstructive cardiomyopathy. The Pacing in Cardiomyopathy study was initiated to explore the effects of pacing in a double-blind randomized crossover fashion. The aims were to ascertain the beneficial effects of pacing in a controlled study and to rule out a placebo effect by pacing. This paper deals with the outcome of pacing on quality of life during 1 year of follow-up.
METHODS: Quality of life was evaluated with the Karolinska questionnaire, validated for patients paced for bradyarrhythmias and ischaemic heart disease. Drug-refractory patients with hypertrophic obstructive cardiomyopathy were recruited for the study and after a temporary pacing procedure implanted with permanent pacemakers. Patients were randomized to two study arms defining the sequence of pacemaker programming. In one arm the pacemaker was inactive, in the other active. After 3 months the pacemaker was reprogrammed to the alternate mode and a further 3 months followed. After this period subsequent pacemaker programming corresponded to the mode preferred by the patient. A last assessment was made 1 year after baseline examinations.
RESULTS: Eighty patients completed the first crossover period and 75 completed the full 1 year of follow-up. Active pacing induced significant quality of life improvements, in the order of 9-44%, regardless of programming sequence. Discontinuation of pacing after a first active period resulted in the return of symptoms. Fourteen patients requested early reprogramming after having been programmed to inactive pacing after a first period of active pacing. Seventy-six patients preferred active pacing after the crossover period. A further 6 months of pacing induced progressive improvement in symptoms already favourably influenced.
CONCLUSION: Atrioventricular synchronous pacing has a profound beneficial effect on most domains of quality of life in patients with hypertrophic obstructive cardiomyopathy refractory to drug treatment. Copyright 1999 The European Society of Cardiology.

Entities:  

Mesh:

Year:  1999        PMID: 10381856     DOI: 10.1053/euhj.1998.1331

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  Implantable dual-chamber cardioverter-defibrillator-pacemaker.

Authors:  D Pfeiffer; M Mende; A Hagendorff
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

2.  Unmasking the truth.

Authors:  D Cullington; S Esmail; S Hurren; J G F Cleland; A L Clark; M F Alamgir
Journal:  BMJ Case Rep       Date:  2011-01-12

Review 3.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

4.  Psychometric properties of an established heart disease specific health-related quality of life questionnaire for pacemaker patients.

Authors:  S Höfer; M Anelli-Monti; T Berger; F Hintringer; N Oldridge; W Benzer
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

5.  Clinical predictors of health-related quality of life after pacemaker implantation.

Authors:  Werner Benzer; Neil Oldridge; Michael Anelli Monti; Thomas Berger; Florian Hintringer; Stefan Höfer
Journal:  Wien Klin Wochenschr       Date:  2006-12       Impact factor: 1.704

6.  Comparison of long-term effect of dual-chamber pacing and alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Jan Krejci; Pavel Gregor; David Zemanek; Klaudia Vyskocilova; Karol Curila; Radka Stepanova; Miroslav Novak; Ladislav Groch; Josef Veselka
Journal:  ScientificWorldJournal       Date:  2013-11-11

7.  Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy.

Authors:  James W Malcolmson; Rebecca K Hughes; Abhishek Joshi; Jackie Cooper; Alexander Breitenstein; Matthew Ginks; Steffen E Petersen; Saidi A Mohiddin; Mehul B Dhinoja
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

Review 8.  The Impact of Cardiac Devices on Patients' Quality of Life-A Systematic Review and Meta-Analysis.

Authors:  Kevin Willy; Christian Ellermann; Florian Reinke; Benjamin Rath; Julian Wolfes; Lars Eckardt; Florian Doldi; Felix K Wegner; Julia Köbe; Nexhmedin Morina
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-10

9.  Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators.

Authors:  Peter Magnusson; Stellan Mörner; Fredrik Gadler; Jan Karlsson
Journal:  Health Qual Life Outcomes       Date:  2016-04-14       Impact factor: 3.186

10.  Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

Authors:  Razvan Capota; Sebastian Militaru; Alin Alexandru Ionescu; Monica Rosca; Cristian Baicus; Bogdan Alexandru Popescu; Ruxandra Jurcut
Journal:  Health Qual Life Outcomes       Date:  2020-10-30       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.